COGT · Cogent Biosciences, Inc.
$36.23
-0.50 (-1.36%)
At close · Aug 24
Market Cap
$6.37B
Shares
173.52M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.87M
-65%
FY2020
Net Income
-$328.94M
-28.6%
FY2025
Operating Margin
-1044.33%
-901.3pp
FY2020
Diluted EPS
-$2.16
-11.3%
FY2025
Operating Cash Flow
-$264.44M
-27.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $7.87M | $22.5M | $9.73M | $8.36M | |
| $290.72M | $269.78M | $232.66M | $173.76M | $121.63M | $55.91M | $25.74M | $43.71M | $38.29M | $29.83M | |
| $98.37M | $63.58M | $43.28M | $34.38M | $26.21M | $19.64M | $17.42M | $10.97M | $7.45M | $4.68M | |
| — | $2.6M | $2.5M | $2.3M | $800K | $147K | $720K | $1.29M | $1.32M | $1.17M | |
| — | — | — | — | — | — | $4.17M | — | — | — | |
| $389.09M | $333.36M | $275.94M | $208.13M | $147.84M | $75.55M | $90.07M | $54.68M | $45.74M | $34.51M | |
| -$389.09M | -$333.36M | -$275.94M | -$208.13M | -$147.84M | -$75.55M | -$82.2M | -$32.18M | -$36.01M | -$26.15M | |
| — | — | — | — | — | — | -1044.33% | -143.02% | -369.89% | -312.82% | |
| — | -$330.76M | -$273.44M | -$205.83M | -$147.04M | -$75.4M | -$81.48M | -$30.89M | -$34.68M | -$24.98M | |
| — | $3.06M | — | — | — | — | — | — | — | — | |
| $24.43M | $14.69M | $18.09M | $13.08M | $3.99M | $467K | $144K | $267K | $1.15M | $386K | |
| $11.91M | $4.43M | $20.08M | $15.72M | $7.6M | $3.28M | $7.39M | $345K | $1.47M | $660K | |
| — | $0 | — | — | — | — | — | — | — | — | |
| -$377.18M | -$328.94M | -$255.86M | -$192.41M | -$140.24M | -$72.27M | -$74.81M | -$31.83M | -$34.53M | -$25.49M | |
| — | — | — | — | — | — | -950.43% | -141.49% | -354.76% | -304.93% | |
| -$242.3M | — | — | -$192.41M | -$140.24M | -$72.27M | -$179.21M | -$31.83M | -$34.55M | -$25.56M | |
| -$377.96M | -$329.03M | -$255.66M | -$192.06M | -$140.35M | -$72.27M | -$74.81M | -$31.82M | -$34.53M | -$25.48M | |
| USD/shares | — | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | — | — | — | — |
| USD/shares | — | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | — | — | — | — |
| shares | — | 128.9M | 103.86M | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 2.55M |
| shares | — | 128.9M | 103.86M | 79.66M | 58.74M | 38.73M | 11.08M | 7.62M | 6.22M | 2.55M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 9.26×
EV/EBIT
—
Peer median 23.88×
P/E (TTM)
—
Peer median 18.90×
Peer medians compare against the 173 similar-size Biotechnology companies (of 517 listed).
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Latestage Development | $120,059,000 | $120,862,000 | $85,484,000 | $61,270,000 |
| Research and Development Personnel Related | $64,035,000 | $47,048,000 | $38,206,000 | $26,421,000 |
| Stock-Based Compensation Expense | $46,079,000 | $39,740,000 | $30,621,000 | $18,367,000 |
| Other Operational Infrastructure and Advisory Support | $40,429,000 | $26,886,000 | $23,010,000 | $21,605,000 |
| Early Stage Preclinical and Discovery Programs | $40,112,000 | $28,141,000 | $19,171,000 | $12,957,000 |
| Research And Development Software Facilities And Other Strategic Support | $20,085,000 | $10,812,000 | $9,374,000 | $6,377,000 |
| Depreciation Expense | $2,564,000 | $2,450,000 | $2,264,000 | $842,000 |
Key facts
CIK
1622229
CUSIP
19240Q201
13F (30d)
317 filings
297 filers
Visit website
Investor relations